Logo image of LQDA

LIQUIDIA CORP (LQDA) Stock Fundamental Analysis

NASDAQ:LQDA - Nasdaq - US53635D2027 - Common Stock - Currency: USD

16.115  -0.39 (-2.33%)

After market: 16.11 0 (-0.03%)

Fundamental Rating

3

Overall LQDA gets a fundamental rating of 3 out of 10. We evaluated LQDA against 194 industry peers in the Pharmaceuticals industry. LQDA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. LQDA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

LQDA had negative earnings in the past year.
LQDA had a negative operating cash flow in the past year.
In the past 5 years LQDA always reported negative net income.
LQDA had a negative operating cash flow in each of the past 5 years.
LQDA Yearly Net Income VS EBIT VS OCF VS FCFLQDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

LQDA's Return On Assets of -47.24% is on the low side compared to the rest of the industry. LQDA is outperformed by 62.16% of its industry peers.
The Return On Equity of LQDA (-108.10%) is worse than 61.08% of its industry peers.
Industry RankSector Rank
ROA -47.24%
ROE -108.1%
ROIC N/A
ROA(3y)-45%
ROA(5y)-52.84%
ROE(3y)-88.11%
ROE(5y)-96.94%
ROIC(3y)N/A
ROIC(5y)N/A
LQDA Yearly ROA, ROE, ROICLQDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 200 -200

1.3 Margins

LQDA has a better Gross Margin (64.65%) than 69.19% of its industry peers.
LQDA's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for LQDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.65%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.31%
GM growth 5Y-2.67%
LQDA Yearly Profit, Operating, Gross MarginsLQDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 -2K -4K -6K -8K

More info and screens

4

2. Health

2.1 Basic Checks

LQDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
LQDA has more shares outstanding than it did 1 year ago.
The number of shares outstanding for LQDA has been increased compared to 5 years ago.
LQDA has a worse debt/assets ratio than last year.
LQDA Yearly Shares OutstandingLQDA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
LQDA Yearly Total Debt VS Total AssetsLQDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

An Altman-Z score of 2.32 indicates that LQDA is not a great score, but indicates only limited risk for bankruptcy at the moment.
The Altman-Z score of LQDA (2.32) is better than 69.73% of its industry peers.
A Debt/Equity ratio of 0.90 indicates that LQDA is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.90, LQDA is not doing good in the industry: 72.43% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF N/A
Altman-Z 2.32
ROIC/WACCN/A
WACC9.65%
LQDA Yearly LT Debt VS Equity VS FCFLQDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M

2.3 Liquidity

LQDA has a Current Ratio of 6.33. This indicates that LQDA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.33, LQDA is in the better half of the industry, outperforming 71.89% of the companies in the same industry.
A Quick Ratio of 6.33 indicates that LQDA has no problem at all paying its short term obligations.
LQDA has a Quick ratio of 6.33. This is in the better half of the industry: LQDA outperforms 73.51% of its industry peers.
Industry RankSector Rank
Current Ratio 6.33
Quick Ratio 6.33
LQDA Yearly Current Assets VS Current LiabilitesLQDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M

More info and screens

6

3. Growth

3.1 Past

LQDA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -87.36%.
LQDA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -14.79%.
LQDA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 45.20% yearly.
EPS 1Y (TTM)-87.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
Revenue 1Y (TTM)-14.79%
Revenue growth 3Y186.97%
Revenue growth 5Y45.2%
Sales Q2Q%20.94%

3.2 Future

The Earnings Per Share is expected to grow by 19.96% on average over the next years. This is quite good.
LQDA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 87.35% yearly.
EPS Next Y-32.6%
EPS Next 2Y-11.17%
EPS Next 3Y18.89%
EPS Next 5Y19.96%
Revenue Next Year-10.25%
Revenue Next 2Y66.34%
Revenue Next 3Y107.31%
Revenue Next 5Y87.35%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
LQDA Yearly Revenue VS EstimatesLQDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
LQDA Yearly EPS VS EstimatesLQDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for LQDA. In the last year negative earnings were reported.
Also next year LQDA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LQDA Price Earnings VS Forward Price EarningsLQDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LQDA Per share dataLQDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 -1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as LQDA's earnings are expected to grow with 18.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.17%
EPS Next 3Y18.89%

More info and screens

0

5. Dividend

5.1 Amount

LQDA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LIQUIDIA CORP

NASDAQ:LQDA (2/21/2025, 8:00:00 PM)

After market: 16.11 0 (-0.03%)

16.115

-0.39 (-2.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13 2024-11-13/bmo
Earnings (Next)03-13 2025-03-13/amc
Inst Owners61.89%
Inst Owner Change-98.1%
Ins Owners4.02%
Ins Owner Change2.86%
Market Cap1.36B
Analysts85
Price Target25.84 (60.35%)
Short Float %18.78%
Short Ratio13.18
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.59%
Min EPS beat(2)-6.02%
Max EPS beat(2)21.21%
EPS beat(4)1
Avg EPS beat(4)-31.65%
Min EPS beat(4)-75.11%
Max EPS beat(4)21.21%
EPS beat(8)2
Avg EPS beat(8)-27.28%
EPS beat(12)4
Avg EPS beat(12)-25.41%
EPS beat(16)6
Avg EPS beat(16)-19.04%
Revenue beat(2)1
Avg Revenue beat(2)-28.96%
Min Revenue beat(2)-62.04%
Max Revenue beat(2)4.12%
Revenue beat(4)1
Avg Revenue beat(4)-24.41%
Min Revenue beat(4)-62.04%
Max Revenue beat(4)4.12%
Revenue beat(8)4
Avg Revenue beat(8)-6.14%
Revenue beat(12)7
Avg Revenue beat(12)-3.92%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.13%
PT rev (3m)0%
EPS NQ rev (1m)4.11%
EPS NQ rev (3m)4.11%
EPS NY rev (1m)0.62%
EPS NY rev (3m)5.94%
Revenue NQ rev (1m)-0.59%
Revenue NQ rev (3m)0.24%
Revenue NY rev (1m)0.93%
Revenue NY rev (3m)1.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 87.38
P/FCF N/A
P/OCF N/A
P/B 12.34
P/tB 13.19
EV/EBITDA N/A
EPS(TTM)-1.63
EYN/A
EPS(NY)-1.48
Fwd EYN/A
FCF(TTM)-1.09
FCFYN/A
OCF(TTM)-1.05
OCFYN/A
SpS0.18
BVpS1.31
TBVpS1.22
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -47.24%
ROE -108.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.65%
FCFM N/A
ROA(3y)-45%
ROA(5y)-52.84%
ROE(3y)-88.11%
ROE(5y)-96.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y7.31%
GM growth 5Y-2.67%
F-Score2
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 177%
Cap/Sales 24.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.33
Quick Ratio 6.33
Altman-Z 2.32
F-Score2
WACC9.65%
ROIC/WACCN/A
Cap/Depr(3y)178.83%
Cap/Depr(5y)126.49%
Cap/Sales(3y)23.04%
Cap/Sales(5y)38.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-87.36%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-25%
EPS Next Y-32.6%
EPS Next 2Y-11.17%
EPS Next 3Y18.89%
EPS Next 5Y19.96%
Revenue 1Y (TTM)-14.79%
Revenue growth 3Y186.97%
Revenue growth 5Y45.2%
Sales Q2Q%20.94%
Revenue Next Year-10.25%
Revenue Next 2Y66.34%
Revenue Next 3Y107.31%
Revenue Next 5Y87.35%
EBIT growth 1Y-108.84%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-93.43%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-191.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-180.8%
OCF growth 3YN/A
OCF growth 5YN/A